D. SuriyachanA. ThithapandhaMahidol University2018-03-222018-03-221977-01-01Toxicology and Applied Pharmacology. Vol.41, No.2 (1977), 369-376109603330041008X2-s2.0-0017724286https://repository.li.mahidol.ac.th/handle/20.500.14594/10336Cobaltous chloride (60 mg/kg, sc, daily for 2 days), which was found to effectively decrease the microsomal cytochrome P-450 content of mouse liver to approximately half of its normal value and which impaired the oxidative metabolism or hydroxylation of aminopyrine, ethylmorphine, and hexobarbital, offered no protection against CCl 4 -induced liver damage. However, this hemoprotein inhibitor had no effect on the rate of reduction of cytochrome P-450 by NADPH and exerted a slight effect on aniline hydroxylation. SKF-525A (50 mg/kg, ip) also failed to protect against CCl 4 hepatotoxicity though it has been shown to inhibit the hydroxylation of a number of substrates. This inhibitor, a type I compound, was found to enhance cytochrome P-450 reduction by NADPH. Further studies revealed that CCl 4 -induced hepatic injury could be prevented by phenazine methosulfate (2 mg/kg, ip, 5 doses at 0.5-hr intervals), which in vitro was found to inhibit NADPH-cytochrome c reductase noncompetitively. All of these findings are not satisfactorily explainable by electron transfer from NADPH-cytochrome c reductase to CCl 4 as the activation reaction for CCl 4 but are compatible with the hypothesis previously proposed by others that cytochrome P-450 is the critical site for CCl 4 activation. © 1977.Mahidol UniversityPharmacology, Toxicology and PharmaceuticsArticleSCOPUS10.1016/0041-008X(77)90038-2